Ebola outbreak on track to be deadliest ever, WHO chief says - BBC News

• The author argues that current disease burdens are essentially policy failures, suggesting that medical progress is being unnecessarily hindered. • A primary bottleneck identified is the increasing complexity and slowing pace of clinical trials required for drug approval.

• Valion Bio is launching a shielded-mouse study this week to evaluate the efficacy of Entolimod in improving survival and gastrointestinal recovery following radiation exposure. • The study has received necessary approvals from the Armed Forces Radiobiology Information Institute (AFRRI) and the Institutional Animal Care and Use Committee (IACUC).

• A U.S. study highlights the high economic burden of measles outbreaks, estimating that a single event can cost millions of dollars in healthcare and public-health response. • Global health efforts are shifting toward infectious disease preparedness, including the U.S. FDA's approval of Moderna’s first mRNA influenza vaccine.

• Researchers publishing in JAMA Network Open found that noncitizens in the U.S. have lower screening rates for cervical, colorectal, and breast cancers due to socioeconomic barriers and limited healthcare access. • The FDA has declined to approve 177Lu-edotreotide, an investigational radiotherapeutic for gastroenteropancreatic neuroendocrine tumors, citing specific manufacturing issues.

• The AACR will host a participant training and advocate reception on September 16, followed by "Rally Hill Day" on September 17. • During the event, participants will meet with congressional offices to advocate for sustained National Institutes of Health (NIH) funding.

• The provided text discusses a commentary or excerpt involving Dr. Suzanne Humphries and potentially Pierre Kory regarding their book "Sacrifice." • The author argues that while individual accounts are not clinical trials, they serve as critical warnings that should prompt formal scientific research.

• A new "double-punch" strategy using specialized particles to target aggressive brain cancer has shown promise, according to a recent study. • A randomized trial involving 315 overweight Chinese adults aged 18+ found that a single focused workout can provide meaningful health benefits for those with central obesity.

• NanoViricides, Inc. (NYSE American: NNVC) received regulatory approval on August 10, 2026, to launch a Phase II clinical trial for its NV-387 oral gummies. • The trial will take place in the Democratic Republic of Congo to treat patients affected by the current largest and most rapidly expanding Ebola outbreak.

• GlobalRPH has released a curated list of the top 20 medical news topics for clinicians covering the week of August 3-9, 2026. • The update includes a specific focus on the changing geography of sexually transmitted infections (STIs) within the United States.

• NanoViricides, Inc. (NASDAQ:NNVC) has received regulatory approval to initiate a Phase II Clinical Trial for NV-387 oral gummies. • The drug is being developed as a treatment for the Bundibugyo Ebola virus, addressing an urgent need for effective antivirals during the current outbreak in the Democratic Republic of the Congo.

• Bipartisan House Armed Services Committee amendments propose using the 2027 National Defense Authorization Act to extend military clinical trials of MDMA and psilocybin for active-duty service members. • Louisiana launched a regulated clinical pilot program this week using psilocybin and related compounds to treat substance use and treatment-resistant mental health conditions, funded by opioid-settlement money.